Titre : Cytochrome P-450 CYP1B1

Cytochrome P-450 CYP1B1 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Vascular System Injuries
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cytochrome P-450 CYP1B1 : Questions médicales les plus fréquentes", "headline": "Cytochrome P-450 CYP1B1 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cytochrome P-450 CYP1B1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-12", "dateModified": "2025-03-07", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cytochrome P-450 CYP1B1" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Famille-1 de cytochromes P450", "url": "https://questionsmedicales.fr/mesh/D000072461", "about": { "@type": "MedicalCondition", "name": "Famille-1 de cytochromes P450", "code": { "@type": "MedicalCode", "code": "D000072461", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.422.220.453.100" } } }, "about": { "@type": "MedicalCondition", "name": "Cytochrome P-450 CYP1B1", "alternateName": "Cytochrome P-450 CYP1B1", "code": { "@type": "MedicalCode", "code": "D065633", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Purnima Singh", "url": "https://questionsmedicales.fr/author/Purnima%20Singh", "affiliation": { "@type": "Organization", "name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)." } }, { "@type": "Person", "name": "Shubha Ranjan Dutta", "url": "https://questionsmedicales.fr/author/Shubha%20Ranjan%20Dutta", "affiliation": { "@type": "Organization", "name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)." } }, { "@type": "Person", "name": "Chi Young Song", "url": "https://questionsmedicales.fr/author/Chi%20Young%20Song", "affiliation": { "@type": "Organization", "name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)." } }, { "@type": "Person", "name": "Frank J Gonzalez", "url": "https://questionsmedicales.fr/author/Frank%20J%20Gonzalez", "affiliation": { "@type": "Organization", "name": "Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)." } }, { "@type": "Person", "name": "Kafait U Malik", "url": "https://questionsmedicales.fr/author/Kafait%20U%20Malik", "affiliation": { "@type": "Organization", "name": "" } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "How vascular smooth muscle cell phenotype switching contributes to vascular disease.", "datePublished": "2022-11-21", "url": "https://questionsmedicales.fr/article/36411459", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12964-022-00993-2" } }, { "@type": "ScholarlyArticle", "name": "Brain autopsies of critically ill COVID-19 patients demonstrate heterogeneous profile of acute vascular injury, inflammation and age-linked chronic brain diseases.", "datePublished": "2022-12-17", "url": "https://questionsmedicales.fr/article/36528671", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s40478-022-01493-7" } }, { "@type": "ScholarlyArticle", "name": "Liquid plasma promotes angiogenesis through upregulation of endothelial nitric oxide synthase-induced extracellular matrix metabolism: potential applications of liquid plasma for vascular injuries.", "datePublished": "2024-02-19", "url": "https://questionsmedicales.fr/article/38374138", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12964-023-01412-w" } }, { "@type": "ScholarlyArticle", "name": "Proximal humeral fractures with vascular compromise.", "datePublished": "2024-08-01", "url": "https://questionsmedicales.fr/article/39084641", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1302/0301-620X.106B8.BJJ-2023-1114.R1" } }, { "@type": "ScholarlyArticle", "name": "Identification of Potentially Functional Circular RNA/Long Noncoding RNA-MicroRNA-mRNA Regulatory Networks Associated with Vascular Injury in Type 2 Diabetes Mellitus by Integrated Microarray Analysis.", "datePublished": "2023-03-10", "url": "https://questionsmedicales.fr/article/36937538", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1155/2023/3720602" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Hémoprotéines", "item": "https://questionsmedicales.fr/mesh/D006420" }, { "@type": "ListItem", "position": 5, "name": "Cytochromes", "item": "https://questionsmedicales.fr/mesh/D003580" }, { "@type": "ListItem", "position": 6, "name": "Cytochrome P-450 enzyme system", "item": "https://questionsmedicales.fr/mesh/D003577" }, { "@type": "ListItem", "position": 7, "name": "Famille-1 de cytochromes P450", "item": "https://questionsmedicales.fr/mesh/D000072461" }, { "@type": "ListItem", "position": 8, "name": "Cytochrome P-450 CYP1B1", "item": "https://questionsmedicales.fr/mesh/D065633" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cytochrome P-450 CYP1B1 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cytochrome P-450 CYP1B1", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cytochrome P-450 CYP1B1", "description": "Comment diagnostiquer une anomalie de CYP1B1 ?\nQuels tests sont utilisés pour évaluer CYP1B1 ?\nQuels symptômes indiquent un problème avec CYP1B1 ?\nY a-t-il des marqueurs biologiques pour CYP1B1 ?\nLe diagnostic de CYP1B1 est-il complexe ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Vascular+System+Injuries&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cytochrome P-450 CYP1B1", "description": "Quels symptômes sont liés à une mutation de CYP1B1 ?\nLes symptômes de CYP1B1 varient-ils selon les individus ?\nCYP1B1 peut-il affecter le métabolisme des médicaments ?\nQuels signes cliniques sont associés à CYP1B1 ?\nLes symptômes de CYP1B1 sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Vascular+System+Injuries&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cytochrome P-450 CYP1B1", "description": "Comment prévenir les troubles liés à CYP1B1 ?\nLe mode de vie influence-t-il CYP1B1 ?\nDes vaccinations peuvent-elles aider avec CYP1B1 ?\nLe suivi médical régulier est-il important pour CYP1B1 ?\nLes conseils génétiques sont-ils utiles pour CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Vascular+System+Injuries&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cytochrome P-450 CYP1B1", "description": "Quels traitements existent pour les troubles liés à CYP1B1 ?\nPeut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?\nY a-t-il des traitements préventifs pour CYP1B1 ?\nLes traitements sont-ils efficaces pour tous les patients ?\nDes thérapies alternatives sont-elles disponibles pour CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Vascular+System+Injuries&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cytochrome P-450 CYP1B1", "description": "Quelles complications peuvent survenir avec CYP1B1 ?\nLes complications de CYP1B1 sont-elles graves ?\nComment gérer les complications liées à CYP1B1 ?\nLes complications de CYP1B1 sont-elles prévisibles ?\nY a-t-il des complications à long terme avec CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Vascular+System+Injuries&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cytochrome P-450 CYP1B1", "description": "Quels sont les facteurs de risque pour CYP1B1 ?\nL'hérédité joue-t-elle un rôle dans CYP1B1 ?\nL'exposition à des toxines influence-t-elle CYP1B1 ?\nLe sexe influence-t-il les risques liés à CYP1B1 ?\nL'alimentation a-t-elle un impact sur CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Vascular+System+Injuries&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie de CYP1B1 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses enzymatiques peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer CYP1B1 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de métabolisme des médicaments et les analyses sanguines sont courants." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème avec CYP1B1 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des troubles métaboliques ou des réactions médicamenteuses peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs biologiques pour CYP1B1 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux de certains métabolites peuvent indiquer une dysfonction." } }, { "@type": "Question", "name": "Le diagnostic de CYP1B1 est-il complexe ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il peut être complexe, nécessitant une évaluation clinique et des tests spécialisés." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une mutation de CYP1B1 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles oculaires, des anomalies de développement et des cancers peuvent apparaître." } }, { "@type": "Question", "name": "Les symptômes de CYP1B1 varient-ils selon les individus ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de la gravité de la mutation." } }, { "@type": "Question", "name": "CYP1B1 peut-il affecter le métabolisme des médicaments ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une dysfonction de CYP1B1 peut entraîner des réactions indésirables aux médicaments." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à CYP1B1 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des troubles de la vision et des anomalies cutanées peuvent être observés." } }, { "@type": "Question", "name": "Les symptômes de CYP1B1 sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent être gérés, mais d'autres peuvent être permanents." } }, { "@type": "Question", "name": "Comment prévenir les troubles liés à CYP1B1 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut le dépistage génétique et l'éducation sur les risques." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il CYP1B1 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain peut réduire les risques de complications liées à CYP1B1." } }, { "@type": "Question", "name": "Des vaccinations peuvent-elles aider avec CYP1B1 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les troubles liés à CYP1B1." } }, { "@type": "Question", "name": "Le suivi médical régulier est-il important pour CYP1B1 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier permet de détecter précocement les complications." } }, { "@type": "Question", "name": "Les conseils génétiques sont-ils utiles pour CYP1B1 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils aident à comprendre les risques et à planifier des mesures préventives." } }, { "@type": "Question", "name": "Quels traitements existent pour les troubles liés à CYP1B1 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent inclure des thérapies géniques et des médicaments spécifiques." } }, { "@type": "Question", "name": "Peut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des ajustements de dosage et des alternatives médicamenteuses peuvent aider." } }, { "@type": "Question", "name": "Y a-t-il des traitements préventifs pour CYP1B1 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils génétiques et un suivi régulier peuvent être des mesures préventives." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces pour tous les patients ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité des traitements peut varier selon la gravité de la condition." } }, { "@type": "Question", "name": "Des thérapies alternatives sont-elles disponibles pour CYP1B1 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certaines thérapies alternatives peuvent être explorées, mais leur efficacité n'est pas prouvée." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec CYP1B1 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des cancers et des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Les complications de CYP1B1 sont-elles graves ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être graves et nécessiter une intervention médicale." } }, { "@type": "Question", "name": "Comment gérer les complications liées à CYP1B1 ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut un suivi médical, des traitements symptomatiques et des interventions." } }, { "@type": "Question", "name": "Les complications de CYP1B1 sont-elles prévisibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être prévisibles avec un suivi approprié." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme avec CYP1B1 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme peuvent affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour CYP1B1 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et l'exposition environnementale." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans CYP1B1 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les mutations de CYP1B1 peuvent être héritées, augmentant le risque de troubles." } }, { "@type": "Question", "name": "L'exposition à des toxines influence-t-elle CYP1B1 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certaines toxines peut affecter l'activité de CYP1B1." } }, { "@type": "Question", "name": "Le sexe influence-t-il les risques liés à CYP1B1 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études montrent que le sexe peut influencer l'expression de CYP1B1." } }, { "@type": "Question", "name": "L'alimentation a-t-elle un impact sur CYP1B1 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines habitudes alimentaires peuvent influencer l'activité de CYP1B1 et le métabolisme." } } ] } ] }

Sources (10000 au total)

Brain autopsies of critically ill COVID-19 patients demonstrate heterogeneous profile of acute vascular injury, inflammation and age-linked chronic brain diseases.

This study examined neuropathological findings of patients who died following hospitalization in an intensive care unit with SARS-CoV-2.... Data originate from 20 decedents who underwent brain autopsy followed by ex-vivo imaging and dissection. Systematic neuropathologic examinations were performed to assess histopathologic changes includ... The mean age-at-death was 66.2 years (range: 26-97 years) and 14 were male. The patient's medical history included cardiovascular risk factors or diseases (n = 11, 55%) and dementia (n = 5, 25%). Brai... Acute tissue injuries and microglial activation were the most common abnormalities in COVID-19 brains. Focal evidence of encephalitis-like changes was noted despite the lack of detectable virus. The m...

Liquid plasma promotes angiogenesis through upregulation of endothelial nitric oxide synthase-induced extracellular matrix metabolism: potential applications of liquid plasma for vascular injuries.

Applications of nonthermal plasma have expanded beyond the biomedical field to include antibacterial, anti-inflammatory, wound healing, and tissue regeneration. Plasma enhances epithelial cell repair;... This study assessed whether liquid plasma (LP) increased nitric oxide (NO) production in human umbilical vein endothelial cells by modulating endothelial NO synthase (eNOS) phosphorylation and potenti... The present study suggests that LP treatment may be a novel strategy for promoting angiogenesis in vascular damage. Video Abstract....

Proximal humeral fractures with vascular compromise.

Vascular compromise due to arterial injury is a rare but serious complication of a proximal humeral fracture. The aims of this study were to report its incidence in a large urban population, and to id... A total of 3,497 adult patients with a proximal humeral fracture were managed between January 2015 and December 2022 in a single tertiary trauma centre. Their mean age was 66.7 years (18 to 103) and 2... A total of 18 patients (0.5%) had a proximal humeral fracture and clinical evidence of vascular compromise, giving an annual incidence of 0.29 per 100,000 of the population. Their mean age was 68.7 ye... The classic signs of distal ischaemia are often absent in patients with proximal injuries to major vessels. We were able to identify specific clinical and radiological 'red flags' which, particularly ...

Identification of Potentially Functional Circular RNA/Long Noncoding RNA-MicroRNA-mRNA Regulatory Networks Associated with Vascular Injury in Type 2 Diabetes Mellitus by Integrated Microarray Analysis.

This research is aimed at figuring out the potential circular RNA (circRNA)/long noncoding RNA- (lncRNA-) microRNA- (miRNA-) mRNA regulatory networks associated with a vascular injury in type 2 diabet...

Role of Nuclear Receptor Subfamily 1 Group D Member 1 in the Proliferation, Migration of Vascular Smooth Muscle Cell, and Vascular Intimal Hyperplasia.

Excessive proliferation and migration of vascular smooth muscle cells (VSMCs) cause neointimal hyperplasia after percutaneous vascular interventions. Nuclear receptor subfamily 1 group D member 1 (NR1...

Outcomes of vascular trauma associated with an evolution in the use of endovascular management.

The availability of endovascular techniques has led to a paradigm shift in the management of vascular injury. Although previous reports showed trends towards the increased use of catheter-based techni... The American Association for the Surgery of Trauma (AAST) Prospective Observational Vascular Injury Treatment registry (PROOVIT) is the only large multicenter database focusing specifically on the man... Of the 3249 patients included, 76% were male, and overall treatment type was 42% nonoperative, 44% open, and 14% endovascular. Endovascular treatment increased an average of 2% per year from 2013 to 2... The reported use of endovascular techniques within the PROOVIT registry increased more than 10% over a 6-year period. This increase was associated with improved survival, especially for patients with ...

Predictive Factors of Amputation in Infrainguinal Vascular Trauma: A Monocentric Experience.

Infrainguinal vascular injuries (IIVIs) are emergencies involving both functional and vital prognosis. The choice between saving the limb or doing a first-line amputation is difficult even for an expe... Between 2010 and 2017, we reviewed retrospectively patients with IIVI. The main criteria for judgment were as follows: primary, secondary, and overall amputation. Two groups of potential risk factors ... Fifty-seven IIVIs were found in 54 patients. The mean ISS was 32,3 ± 21. A primary amputation was performed in 19%, and secondary in 14% of cases. Overall amputation rate was 35% (n = 19). Multivariat... The ISS is a good predictor of the risk of amputation in IIVI. A threshold of 41 is an objective criterion helping to decide for a first-line amputation. Advanced age and hemodynamic instability shoul...